Published in J Inherit Metab Dis on February 04, 2012
Sterols and oxysterols in immune cell function. Nat Immunol (2013) 1.41
Advances in Fmoc solid-phase peptide synthesis. J Pept Sci (2016) 0.95
Structure of PatF from Prochloron didemni. Acta Crystallogr Sect F Struct Biol Cryst Commun (2013) 0.92
Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol (2014) 0.91
Enzymes of the AKR1B and AKR1C Subfamilies and Uterine Diseases. Front Pharmacol (2012) 0.84
Increased RhoA prenylation in the loechrig (loe) mutant leads to progressive neurodegeneration. PLoS One (2012) 0.81
Innovative Target Therapies Are Able to Block the Inflammation Associated with Dysfunction of the Cholesterol Biosynthesis Pathway. Int J Mol Sci (2015) 0.75
Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17
Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature (2003) 12.10
Small GTP-binding proteins. Physiol Rev (2001) 9.52
Lamin a truncation in Hutchinson-Gilford progeria. Science (2003) 8.01
cDNA sequencing of nuclear lamins A and C reveals primary and secondary structural homology to intermediate filament proteins. Proc Natl Acad Sci U S A (1986) 5.07
Rho GTPases in neuronal morphogenesis. Nat Rev Neurosci (2000) 4.33
Trafficking and signaling by fatty-acylated and prenylated proteins. Nat Chem Biol (2006) 4.11
Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell (1990) 3.99
Life at the edge: the nuclear envelope and human disease. Nat Rev Mol Cell Biol (2002) 3.84
Role of lipid modifications in targeting proteins to detergent-resistant membrane rafts. Many raft proteins are acylated, while few are prenylated. J Biol Chem (1999) 3.81
LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet (2000) 3.73
Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J Biol Chem (1993) 3.70
Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A (2005) 3.64
A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. EMBO J (1991) 3.64
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther (2001) 3.59
Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med (2008) 3.34
Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci U S A (2005) 3.30
Nuclear lamins: laminopathies and their role in premature ageing. Physiol Rev (2006) 3.30
Prenyl proteins in eukaryotic cells: a new type of membrane anchor. Trends Biochem Sci (1990) 3.12
Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet (2000) 3.08
Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med (1995) 2.99
Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet (2002) 2.90
Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc Natl Acad Sci U S A (2005) 2.85
A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science (2006) 2.71
Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum Mol Genet (2005) 2.69
Farnesylated gamma-subunit of photoreceptor G protein indispensable for GTP-binding. Nature (1990) 2.57
Post-prenylation-processing enzymes as new targets in oncogenesis. Nat Rev Cancer (2005) 2.47
The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin. PLoS One (2007) 2.41
A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest (2006) 2.39
Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia. Hum Mol Genet (2003) 2.36
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol (2004) 2.32
Sequence requirement for peptide recognition by rat brain p21ras protein farnesyltransferase. Proc Natl Acad Sci U S A (1991) 2.27
The processing pathway of prelamin A. J Cell Sci (1994) 2.25
Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J (1990) 2.17
The CaaX motif of lamin A functions in conjunction with the nuclear localization signal to target assembly to the nuclear envelope. Cell (1989) 2.12
The role of isoprenylation in membrane attachment of nuclear lamins. A single point mutation prevents proteolytic cleavage of the lamin A precursor and confers membrane binding properties. J Cell Sci (1994) 2.10
Isoprenylcysteine carboxyl methyltransferase deficiency in mice. J Biol Chem (2000) 2.09
Nuclear envelope disorganization in fibroblasts from lipodystrophic patients with heterozygous R482Q/W mutations in the lamin A/C gene. J Cell Sci (2001) 2.07
Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of Lamin A precursors. Hum Mol Genet (2005) 2.06
Nucleoplasmic localization of prelamin A: implications for prenylation-dependent lamin A assembly into the nuclear lamina. Proc Natl Acad Sci U S A (1992) 2.05
Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A (2005) 2.05
Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I. J Lipid Res (2006) 2.05
An alternative splicing product of the lamin A/C gene lacks exon 10. J Biol Chem (1996) 1.98
Modification of nuclear lamin proteins by a mevalonic acid derivative occurs in reticulocyte lysates and requires the cysteine residue of the C-terminal CXXM motif. EMBO J (1989) 1.96
Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy. Hum Mol Genet (2004) 1.94
Isoprenylated proteins. Cell Mol Life Sci (2006) 1.90
Disruption of the mouse Rce1 gene results in defective Ras processing and mislocalization of Ras within cells. J Biol Chem (1999) 1.90
Isoprenylation is required for the processing of the lamin A precursor. J Cell Biol (1990) 1.90
Targeted inactivation of the isoprenylcysteine carboxyl methyltransferase gene causes mislocalization of K-Ras in mammalian cells. J Biol Chem (2000) 1.79
Incorporation of a product of mevalonic acid metabolism into proteins of Chinese hamster ovary cell nuclei. J Cell Biol (1988) 1.78
Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem (2000) 1.78
The Rac-RhoGDI complex and the structural basis for the regulation of Rho proteins by RhoGDI. Nat Struct Biol (2000) 1.77
Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem (1995) 1.74
Role of A-type lamins in signaling, transcription, and chromatin organization. J Cell Biol (2009) 1.68
Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell (1994) 1.67
Identification and cloning of an mRNA coding for a germ cell-specific A-type lamin in mice. Exp Cell Res (1994) 1.66
The gamma subunit of transducin is farnesylated. Proc Natl Acad Sci U S A (1990) 1.66
The conserved carboxy-terminal cysteine of nuclear lamins is essential for lamin association with the nuclear envelope. J Cell Biol (1989) 1.63
Thematic review series: lipid posttranslational modifications. geranylgeranylation of Rab GTPases. J Lipid Res (2006) 1.60
Towards complete sets of farnesylated and geranylgeranylated proteins. PLoS Comput Biol (2007) 1.57
Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol Cell Biol (2002) 1.56
Altered pre-lamin A processing is a common mechanism leading to lipodystrophy. Hum Mol Genet (2005) 1.54
The role of Rho GTPases in disease development. Gene (2002) 1.51
Fatty acylation and prenylation of proteins: what's hot in fat. Curr Opin Cell Biol (2005) 1.50
Structural organization of the human gene (LMNB1) encoding nuclear lamin B1. Genomics (1995) 1.48
New approaches to progeria. Pediatrics (2007) 1.47
Isoprenylation of a protein kinase. Requirement of farnesylation/alpha-carboxyl methylation for full enzymatic activity of rhodopsin kinase. J Biol Chem (1992) 1.45
Recent advances in the study of prenylated proteins. Biochim Biophys Acta (2000) 1.43
The chemical toolbox for monitoring protein fatty acylation and prenylation. Nat Chem Biol (2010) 1.42
A- and B-type lamins are differentially expressed in normal human tissues. Histochem Cell Biol (1997) 1.40
The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem (1997) 1.35
Alterations of nuclear envelope and chromatin organization in mandibuloacral dysplasia, a rare form of laminopathy. Physiol Genomics (2005) 1.34
Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells. Proc Natl Acad Sci U S A (1996) 1.33
Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem (1995) 1.33
Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation. Biochim Biophys Acta (2007) 1.33
Role of nuclear lamina-cytoskeleton interactions in the maintenance of cellular strength. Biochim Biophys Acta (2006) 1.32
Prenylation of Rab GTPases: molecular mechanisms and involvement in genetic disease. FEBS Lett (2001) 1.29
Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. Curr Med Chem (2008) 1.27
The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. Annu Rev Pharmacol Toxicol (1997) 1.27
Direct synthesis of lamin A, bypassing prelamin a processing, causes misshapen nuclei in fibroblasts but no detectable pathology in mice. J Biol Chem (2010) 1.24
Farnesyltransferase inhibitor as anticancer agent. Mini Rev Med Chem (2009) 1.14
GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res (1997) 1.11
CAAX geranylgeranyl transferase transfers farnesyl as efficiently as geranylgeranyl to RhoB. J Biol Chem (1995) 1.10
Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res (1998) 1.10
Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell Mol Life Sci (2001) 1.06
Tailoring Ras-pathway--inhibitor combinations for cancer therapy. Drug Resist Updat (2005) 1.06
The C-terminal polylysine region and methylation of K-Ras are critical for the interaction between K-Ras and microtubules. J Biol Chem (2000) 1.06
Palmitoylated cysteine 192 is required for RhoB tumor-suppressive and apoptotic activities. J Biol Chem (2005) 1.04
Palmitoyl acyltransferases, their substrates, and novel assays to connect them (Review). Mol Membr Biol (2009) 1.03
Functional aspects of polyisoprenoid protein substituents: roles in protein-protein interaction and trafficking. Biochim Biophys Acta (2000) 1.01
Farnesyltransferase inhibitors: where are we now? Expert Opin Investig Drugs (2010) 0.98
Analysis of the kinetic mechanism of recombinant human isoprenylcysteine carboxylmethyltransferase (Icmt). BMC Biochem (2004) 0.98
Polylysine domain of K-ras 4B protein is crucial for malignant transformation. Proc Natl Acad Sci U S A (1994) 0.91
Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. Ann Hematol (2008) 0.88
Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice. Cancer Chemother Pharmacol (1999) 0.83
The strange case of the "lumper" lamin A/C gene and human premature ageing. Trends Mol Med (2003) 0.82
Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors. Cancer Res (1996) 0.81
Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer. Br J Cancer (2008) 0.77
Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet (2002) 2.90
Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet (2003) 1.81
Characterisation of mutations in 77 patients with X-linked myotubular myopathy, including a family with a very mild phenotype. Hum Genet (2002) 1.41
Alterations of nuclear envelope and chromatin organization in mandibuloacral dysplasia, a rare form of laminopathy. Physiol Genomics (2005) 1.34
The etiology of acute recurrent pancreatitis in children: a challenge for pediatricians. Pancreas (2011) 1.12
Atypical progeroid syndrome due to heterozygous missense LMNA mutations. J Clin Endocrinol Metab (2009) 1.08
Compound heterozygosity for mutations in LMNA in a patient with a myopathic and lipodystrophic mandibuloacral dysplasia type A phenotype. J Clin Endocrinol Metab (2007) 0.97
Novel mutations of TCOF1 gene in European patients with Treacher Collins syndrome. BMC Med Genet (2011) 0.90
Exclusion of CARD15/NOD2 as a candidate susceptibility gene to psoriasis in the Italian population. Eur J Dermatol (2002) 0.90
Somatic and gonadal mosaicism in Hutchinson-Gilford progeria. Am J Med Genet A (2005) 0.89
The R527H mutation in LMNA gene causes an increased sensitivity to ionizing radiation. Cell Cycle (2008) 0.85
Rapid scanning of myotubularin (MTM1) gene by denaturing high-performance liquid chromatography (DHPLC). Neuromuscul Disord (2002) 0.84
Familial partial lipodystrophy, mandibuloacral dysplasia and restrictive dermopathy feature barrier-to-autointegration factor (BAF) nuclear redistribution. Cell Cycle (2012) 0.83
Gene expression profiling of fibroblasts from a human progeroid disease (mandibuloacral dysplasia, MAD #248370) through cDNA microarrays. Gene Expr (2004) 0.83
The strange case of the "lumper" lamin A/C gene and human premature ageing. Trends Mol Med (2003) 0.82
Skeletal phenotype of mandibuloacral dysplasia associated with mutations in ZMPSTE24. Bone (2010) 0.82
Oct-1 recruitment to the nuclear envelope in adult-onset autosomal dominant leukodystrophy. Biochim Biophys Acta (2012) 0.82
Elbow deformities in a patient with mandibuloacral dysplasia type A. Am J Med Genet A (2010) 0.80
The empowerment of translational research: lessons from laminopathies. Orphanet J Rare Dis (2012) 0.80
Altered chromatin organization and SUN2 localization in mandibuloacral dysplasia are rescued by drug treatment. Histochem Cell Biol (2012) 0.80
Centronuclear myopathies: genotype-phenotype correlation and frequency of defined genetic forms in an Italian cohort. J Neurol (2015) 0.78
Denaturing HPLC in laboratory diagnosis of hereditary angioedema. J Allergy Clin Immunol (2007) 0.77
A pilot beta-thalassaemia screening program in the Albanian population for a health planning program. Acta Haematol (2009) 0.76
CARD15 mutation analysis in an Italian population: Leu1007fsinsC but neither Arg702Trp nor Gly908Arg mutations are associated with Crohn's disease. Inflamm Bowel Dis (2004) 0.76
Analysis of TNF-alpha promoter polymorphisms in the susceptibility to beryllium hypersensitivity. Sarcoidosis Vasc Diffuse Lung Dis (2004) 0.75
Towards the pharmacogenomics of cystic fibrosis. Pharmacogenomics (2002) 0.75
Prenatal diagnosis of Cockayne syndrome type A based on the identification of two novel mutations in the ERCC8 gene. Genet Test Mol Biomarkers (2009) 0.75
Toward the pharmacogenomics of cystic fibrosis--an update. Pharmacogenomics (2004) 0.75